Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 24, 2023 07:05 ET | Source: Kamada Ltd.

Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a...
May 24, 2023 07:00 ET | Source: Kamada Ltd.

Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds

REHOVOT, Israel and HOBOKEN, N.J., May 24, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a...
May 17, 2023 07:00 ET | Source: Kamada Ltd.

Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023

REHOVOT, Israel and HOBOKEN, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products...
May 16, 2023 07:00 ET | Source: Kamada Ltd.

Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland

Switzerland is the first European country to approve Glassia®, which received U.S. FDA approval in 2010Glassia will be commercialized by IDEOGEN AG in Switzerland and the therapy is expected to be...
May 03, 2023 07:00 ET | Source: Kamada Ltd.

Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel

Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021 with Approximately $23 Million in Revenues in 2022, and Gross Margins Over 50%Approval to Manufacture CYTOGAM at Kamada’s...
March 15, 2023 07:10 ET | Source: Kamada Ltd.

Kamada Issues 2023 CEO Letter to Shareholders

REHOVOT, Israel and HOBOKEN, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed...
March 15, 2023 07:00 ET | Source: Kamada Ltd.

Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth

Total Revenues for Fiscal Year 2022 of $129.3 Million Represented Growth of 25% Compared to Fiscal Year 2021; Fourth Quarter 2022 Revenues of $45.4 Million Represented a 44% Increase...
March 09, 2023 08:00 ET | Source: Kamada Ltd.

Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023

REHOVOT, Israel and HOBOKEN, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products...
January 04, 2023 07:00 ET | Source: Kamada Ltd.

Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel

FDA Approval Currently Expected by Mid-2023Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021, with Gross Margins Over 50%Ability to Manufacture CYTOGAM at Kamada’s Facility...
December 19, 2022 07:00 ET | Source: Kamada Ltd.

Kamada Announces Planned Transition of Chief Financial Officer

REHOVOT, Israel and HOBOKEN, N.J., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a vertically integrated global biopharmaceutical company, focused on specialty...